From Grief to Global Change: How the STARS Program Empowers Advocates to Drive Lung Cancer Research

… from a grieving family member into a passionate patient research advocate. Despite not having a background in healthcare or cancer research, Caleb was driven to make a difference. Together with … generating critical data that could shape future cancer research in Nigeria. Today, Caleb is part of the IASLC …

IASLC Launches Beta Version of VIKTOR

IASLC Announces Partnerships to Spur Oncogene-Driven Lung Cancer Research, Address Global Challenges in Conquering Thoracic Cancers

IASLC, LCRF Request Proposals for New Research Grant

Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award Lecture

… Dr. Hirsch’s significant contributions to international research and education. … Renowned Researcher Fred Hirsch Delivers 2022 Heine H. Hansen Award …

Pathology Researcher Keith Kerr Receives 2025 Heine H. Hansen Award

Journal of Thoracic Oncology’s Impact Factor Rises Again; JTO Clinical and Research Reports Receives First Impact Factor

… Oncology’s Impact Factor Rises Again; JTO Clinical and Research Reports Receives First Impact Factor … Erin Jungmeyer …

Tobacco Control Impacts Everyone in Respiratory Medicine, JTO CRR Editor Says

… In a Q&A with ILCN, new JTO Clinical and Research Reports Editor-in-Chief Dr. Emily Stone discusses her … and the importance of open-access journals in elevating research globally. … Tobacco Control Impacts Everyone in …

In Case You Missed It: IASLC Launches New Education Center

Combining SABR with Immunotherapy to Improve Outcomes in Early-Stage NSCLC

… with an early-stage non-small-cell lung cancer (NSCLC), research combining prospective and propensity-matched data has … microenvironment and systemic immune responses. 8  Recent research has focused on specific immune cell subsets, such as … with SABR. Substantial clinical and translational research is essential to establish the true effectiveness and …

IASLC Launches Global Member Survey on Diversity, Equity, and Inclusion

Can pCR Be an Early Clinical Trial Endpoint? Initiative Aims to Answer That Question